We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Vertex Pharmaceuticals (VRTX - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Vertex Pharmaceuticals is a member of our Medical group, which includes 866 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 11.39% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that VRTX has returned about 8.73% since the start of the calendar year. In comparison, Medical companies have returned an average of 0.83%. As we can see, Vertex Pharmaceuticals is performing better than its sector in the calendar year.
Breaking things down more, VRTX is a member of the Medical - Biomedical and Genetics industry, which includes 367 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has lost an average of 2.96% so far this year, so VRTX is performing better in this area.
VRTX will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Vertex Pharmaceuticals (VRTX - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Vertex Pharmaceuticals is a member of our Medical group, which includes 866 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. VRTX is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 11.39% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that VRTX has returned about 8.73% since the start of the calendar year. In comparison, Medical companies have returned an average of 0.83%. As we can see, Vertex Pharmaceuticals is performing better than its sector in the calendar year.
Breaking things down more, VRTX is a member of the Medical - Biomedical and Genetics industry, which includes 367 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has lost an average of 2.96% so far this year, so VRTX is performing better in this area.
VRTX will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.